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Randomized Trial of PES Versus BMS for Unprotected Left Main PCI
In the first published, randomized trial comparing drug-eluting stents (DES) andbare-metal stents (BMS) for unprotected left main disease, Erglis and colleagues
prospectively randomized 103 subjects to BMS or paclitaxel-eluting stent (PES)
implantation. All lesions were predilated with a cutting balloon and intravascular
ultrasound was used to optimize procedural results. There were no in-hospital deaths,
and only 2 deaths (1 in each group) at 6 months. Repeat revascularization procedures
for recurrent angina or ischemia were required at 6 months in 16% of BMS patients
compared to 2% of DES patients, a benefit attributable to a marked reduction in
binary restenosis with the PES (22.0% vs. 5.7%). An accompanying editorial cautions
that larger trials with longer duration are needed before percutaneous coronary inter-
vention (PCI) can be widely advocated as an alternative to coronary artery bypass
grafting for left main disease. See pages 491 and 498.
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Interventional Cardiology
Diabetics With Multivessel Disease at Highest Risk for Stent Thrombosis
In order to understand the risk factors for and frequency of stent thrombosis (ST)after implantation of a sirolimus-eluting stent (SES), researchers in France have
created the EVASTENT registry. This registry enrolls diabetic patients undergoing
SES implantation, and then enrolls a matched, nondiabetic control. For this report,
1,731 patients were followed for an average of 465 days. Stent thrombosis occurred in
45 subjects (2.6%): 23 subacute and 22 late, including 9 cases at 6 months. The
1-year ST rate was 1.8 times higher in diabetic than in nondiabetic patients; diabetics
with multiple-vessel disease were 5 times more likely than nondiabetics with single-
vessel disease to experience ST. Eight cases of ST occurred within 10 days after
withdrawal of dual antiplatelet therapy. This study helps us to define the risk of, and
risk factors for, ST after use of SES, especially the importance of prolonged dual
antiplatelet therapy. See page 501. See figure.
Cardiac Imaging
Quantitative Perfusion Imaging With MRI: Comparison With FFR and QCA
The first pass of gadolinium through the myocardium can be plotted as signalintensity versus time allowing accurate quantification of blood flow in small areas
of myocardium. Myocardial perfusion reserve (MPR) is calculated as the ratio of
simulated stress and rest flows. Costa and colleagues performed MPR analyses on
patients who also underwent fractional flow reserve (FFR) and/or quantitative coro-
nary angiography (QCA).MeanMPRwas significantly lower in segmentswith anFFR
0.75.AnMPRcutoff of 2.04was 93%sensitive and57%specific for anFFR0.75,
with similar results when compared toQCA for a50% stenosis. This study suggests
theMPRmeasured by cardiac magnetic resonance imaging provides important infor-
mation regarding the hemodynamic significance of atherosclerotic lesions. See page
514.
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Preclinical Studies
Endocannabinoid Blockade Reduces Cardiotoxicity of Doxorubicin
Recent studies show that 90% of children treated with doxorubicin (DOX)manifest at least some cardiac toxicity, yet because of its efficacy it is still widely
used.Mukhopadhyay and colleagues hypothesized that the blockade of cannabinoid-1
(CB1) receptors could reduce the toxicity of DOX. Using both hemodynamic data
acquired from a mouse model and in vitro studies, pretreatment with a CB1 blocker
substantially reduced the cardiotoxicity of DOX. CB1 blockade seems to be effective
because the endocannabinoid anandamide is found in high levels in the myocardium
after exposure toDOX.This study suggests thatCB1 antagonistsmay represent a novel
cardioprotective strategy against DOX-induced cardiotoxicity. See page 528. See
figure.
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Preclinical Studies
Steps Toward the Creation of an Antiatherosclerosis Vaccine
Recentwork suggests that B-cell–mediated immunity, particularly against oxidizedlow-density lipoprotein (oxLDL), may protect against atherosclerosis by inhibit-
ing the uptake of oxLDL into macrophages. Caligiuri and colleagues noticed that
phosphorylcholine (PC) seems to be a significant epitope for oxLDL. They combined
PCwith a hapten, an immune response stimulator, which was then injected into an in
vivo mouse model of atherosclerosis. Immunized mice had a 40% decrease in the
extent of atherosclerotic lesions in the proximal aorta. An accompanying editorial
describes some of the rationale and future studies needed for the development of an
effective vaccine against atherosclerosis. See page 540 and 547. See figure.
